Adverse events1,568

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,568

Type	Event	Organ system	Group	Affected	At risk
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg	1	7
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg	1	6
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part B: Voxelotor 900 mg QD	5	25
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part B: Voxelotor 1500 mg QD	3	15
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD	10	51
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD	2	11
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD	5	9
other	Sickle cell anaemia with crisis	Blood and lymphatic system disorders	Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD	10	23
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg	0	7
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg	0	6
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part B: Voxelotor 900 mg QD	2	25
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part B: Voxelotor 1500 mg QD	0	15
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD	0	51
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD	0	11
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD	0	9
other	Acute chest syndrome	Respiratory, thoracic and mediastinal disorders	Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD	0	23
other	Osteonecrosis	Musculoskeletal and connective tissue disorders	Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg	0	7
other	Osteonecrosis	Musculoskeletal and connective tissue disorders	Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg	0	6
other	Osteonecrosis	Musculoskeletal and connective tissue disorders	Part B: Voxelotor 900 mg QD	1	25
other	Osteonecrosis	Musculoskeletal and connective tissue disorders	Part B: Voxelotor 1500 mg QD	0	15

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02850406/events

API reference For AI assistants

Adverse events1,568

Sources 3

Read this list from software.